At a glance
ClinicalIndex Comparison RecordN/ACompleted· 443 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Observational Study on Predictors of Early On-treatment Response and Sustained Virological Response in HCV-infected Patients Receiving Peginterferon Alfa-2a Plus Ribavirin
In Brief
An observational study for Hepatitis C, Chronic. Completed, enrolled 443 participants across 9 sites.
Detailed Summary
This observational study will evaluate predictors of early on-treatment response and sustained virological response in patients with chronic hepatitis C receiving Pegasys (peginterferon alfa-2a) and ribavirin. Data will be collected from patients on treatment (24 or 48 weeks) and 24 weeks after the end of treatment.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic
CountriesBulgaria
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2011
First PostedJul 2011
Primary CompletionJul 2014
TodayJul 2026
First PostedJul 12, 2011
Enrollment StartMay 31, 2011
Primary CompletionJul 31, 2014
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 15.0 years ago